Form 4: Rhythm Pharmaceuticals' Chief Scientific Officer Acquires Stock Options and Restricted Stock Units

Alastair Garfield, Chief Scientific Officer of Rhythm Pharmaceuticals, reports the acquisition of stock options and restricted stock units.

Summary

• Alastair Garfield, the Chief Scientific Officer of Rhythm Pharmaceuticals, filed a Form 4 on February 19, 2025, reporting transactions made on February 14, 2025.
• Garfield acquired 40,000 stock options with an exercise price of $56.69, which vest over four years, becoming fully exercisable on February 14, 2029.
• He also acquired 26,650 restricted stock units (RSUs), which vest in equal installments annually from February 14, 2026, to February 14, 2029.
• The RSUs represent a contingent right to receive one share of Rhythm Pharmaceuticals common stock each.
• A power of attorney was executed on October 1, 2024, granting authority to David Meeker, Jim Flaherty, Hunter Smith, and Stephen Vander Stoep to act on Garfield's behalf for SEC filings.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating confidence in the company's future and aligning executive interests with shareholder value. It is a neutral to slightly positive event.

Positives

• The acquisition of stock options and restricted stock units aligns the executive's interests with those of the shareholders.
• The vesting schedules for both the options and RSUs incentivize long-term commitment and performance from the Chief Scientific Officer.

Future Outlook

The vesting schedules of the stock options and restricted stock units suggest an expectation of continued service and contribution from the Chief Scientific Officer over the next four years.

Industry Context

Stock option and RSU grants are common compensation practices for executives in the pharmaceutical industry, aligning their interests with company performance and shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries.
• Companies like Amgen, Biogen, and Vertex Pharmaceuticals also utilize stock options and RSUs to incentivize their executives.
• The vesting schedules are typical, with four-year vesting periods being common to encourage long-term commitment.

Stakeholder Impact

• Shareholders may view the stock option and RSU grants positively, as they align executive compensation with company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Form 4, Rhythm Pharmaceuticals, Stock Options, Restricted Stock Units, Alastair Garfield, Beneficial Ownership, Officer, RYTM